# Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

> **NCT01168791** · PHASE3 · COMPLETED · sponsor: **Alaunos Therapeutics** · enrollment: 447 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** doxorubicin in combination with palifosfamide-tris
- **DRUG:** doxorubicin in combination with placebo

## Key facts

- **NCT ID:** NCT01168791
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2013-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01168791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01168791, "Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01168791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*